Peptides Won an FDA Advisory Vote. Nothing Is Approved.
The committee favored six of seven peptide families. The vote is nonbinding, the 503A Bulks List has not changed, and no peptide was approved for any use.
The vote at a glance
Seven families. Two forms each. Fourteen questions.
Every family appeared twice—free base and acetate salt. The pair moved together every time.
12
favorable
2
not favorable
0
approvals
The vote, in one page
PCAC considered seven peptide families twice, once as a free base and once as an acetate salt. Both forms received the same tally in every case. FDA's scientific staff had recommended against all seven families before the meeting.
Vote ledger
All seven tallies and reviewed uses
BPC-157
- Reviewed for
- Ulcerative colitis
- Recommendation
- Favorable
- Vote per form
- 8-6-1
KPV
- Reviewed for
- Wound healing and inflammatory conditions
- Recommendation
- Favorable
- Vote per form
- 8-6-1
TB-500
- Reviewed for
- Wound healing
- Recommendation
- Favorable
- Vote per form
- 8-6-1
MOTS-c
- Reviewed for
- Obesity and osteoporosis
- Recommendation
- Favorable
- Vote per form
- 7-5-2
Emideltide / DSIP
- Reviewed for
- Opioid withdrawal, chronic insomnia, narcolepsy
- Recommendation
- Not favorable
- Vote per form
- 6-7-1
Epitalon
- Reviewed for
- Insomnia
- Recommendation
- Favorable
- Vote per form
- 7-4-1
Semax
- Reviewed for
- Cerebral ischemia, migraine, trigeminal neuralgia
- Recommendation
- Favorable
- Vote per form
- 8-5-1
Votes are yes-no-abstention, from FDA's official webcast readbacks. The reviewed use is the nominated use FDA evaluated, not every use promoted online.
| Peptide family | Reviewed for | Recommendation | Vote per form |
|---|---|---|---|
| BPC-157 | Ulcerative colitis | Favorable | 8-6-1 |
| KPV | Wound healing and inflammatory conditions | Favorable | 8-6-1 |
| TB-500 | Wound healing | Favorable | 8-6-1 |
| MOTS-c | Obesity and osteoporosis | Favorable | 7-5-2 |
| Emideltide / DSIP | Opioid withdrawal, chronic insomnia, narcolepsy | Not favorable | 6-7-1 |
| Epitalon | Insomnia | Favorable | 7-4-1 |
| Semax | Cerebral ischemia, migraine, trigeminal neuralgia | Favorable | 8-5-1 |
Votes are yes-no-abstention, from FDA's official webcast readbacks. The reviewed use is the nominated use FDA evaluated, not every use promoted online.
What the committee reviewed
The committee did not vote on peptides for longevity. Each nomination named a substance, form, and medical use. The recommendation stays attached to that narrow question; it does not validate every claim made for the molecule.
Reviewed use versus common marketing
BPC-157
- FDA review focused on
- Ulcerative colitis
- Often marketed for
- Tendon, joint, and soft-tissue recovery
Epitalon
- FDA review focused on
- Insomnia
- Often marketed for
- Telomerase, anti-aging, and longevity
MOTS-c
- FDA review focused on
- Obesity and osteoporosis
- Often marketed for
- Metabolic health and longevity
| Peptide | FDA review focused on | Often marketed for |
|---|---|---|
| BPC-157 | Ulcerative colitis | Tendon, joint, and soft-tissue recovery |
| Epitalon | Insomnia | Telomerase, anti-aging, and longevity |
| MOTS-c | Obesity and osteoporosis | Metabolic health and longevity |
A favorable 503A recommendation is about compounding access for the nominated use. It is not a finding that the marketed use works.
The regulatory path from here
The committee vote was the first decision point, not the last. FDA can decline the recommendation. If it moves forward, the list changes only after notice-and-comment rulemaking is complete.
The regulatory path
The vote is complete. Every legal step that could change the 503A Bulks List is still ahead.
- 01Now
Committee recommendation
Completed July 23–24
Current position
- 02
FDA decision
Accept or decline
No deadline announced
- 03
Proposed rule
Published for comment
Not yet scheduled
- 04
Public comment
Evidence enters the record
Timing depends on a proposal
- 05
Final rule
The list may change
Only here does legal status change
Why the majority broke with FDA staff
The split was over what to do under weak evidence. FDA staff emphasized missing human efficacy data, poorly characterized substances, impurities, aggregation, immunogenicity, and long-term safety gaps. Many favorable voters instead treated supervised compounding as harm reduction for a gray market that already exists.
Where the room split
Same weak evidence. Different access judgment.
0 of 7
families supported by FDA staff
- Human efficacy data were missing or inadequate.
- Identity, purity, aggregation, and characterization were uncertain.
- Immunogenicity and long-term safety remained unresolved.
6 of 7
families favored by committee
- People were already buying research vials outside clinical systems.
- A licensed pharmacy and inspectable facility could reduce product risk.
- Prescribing and follow-up could add accountability missing from the gray market.
The binary vote created no registry, adverse-event requirement, domestic-ingredient rule, or route limit. A cleaner channel may reduce product risk; it does not upgrade the evidence.
Two votes that show the fault line
The outliers are more revealing than the overall score.
Two votes, one committee
The fault line in dots
Emideltide / DSIP
Not favorable
The committee was not an automatic yes. Proposed uses included opioid withdrawal, where weak evidence carried higher stakes.
Semax
Passed
Both neurologists brought in for Semax voted no. The access-policy majority still prevailed.
Each dot is one counted vote. Position is illustrative and does not identify a named committee member.
If you are considering a peptide now
The vote did not change the clinical decision. You still need an exact product, an exact claim, and someone responsible for what happens next.
- 01
Name it: molecule, form, route, dose, pharmacy, and active-ingredient source.
- 02
Match the claim: ask for human evidence for this exact use, not a neighboring molecule, species, or endpoint.
- 03
Start with the diagnosis: compare the peptide with the better-studied first option.
- 04
Check the pharmacy: lot identity, sterility, endotoxin controls, storage, beyond-use date, and recall process.
- 05
Name the owner: who follows you, what gets monitored, and what would make them stop?
Frequently Asked Questions
Did the FDA approve peptides?
No. PCAC recommended that six of seven peptide families be considered for the 503A compounding list. The recommendation is nonbinding and did not approve a drug for any use.
Can I get BPC-157 from a compounding pharmacy now?
The vote did not change what pharmacies may legally compound. The 503A Bulks List changes only after FDA accepts a recommendation and completes rulemaking.
What is the 503A Bulks List?
It is FDA's list of bulk drug substances pharmacies may use for patient-specific compounding under section 503A. Listing concerns access and preparation, not approval or proof of efficacy.
Was Epitalon recommended for anti-aging?
No. Epitalon was reviewed for insomnia. The committee did not evaluate the anti-aging and telomerase claims used to market it online.
Why was emideltide rejected?
Emideltide, also called DSIP, lost 6-7-1 for both forms. Members focused on weak evidence, difficulty characterizing the substance, and the stakes of uses such as opioid withdrawal.
How long until anything changes?
FDA has to accept the recommendations, propose a rule, take public comment, and issue a final rule. No peptide-specific rulemaking date has been announced.